hVIVO Regulatory News (HVO)

hVIVO PLC

("hVIVO" or the "Company")

Director's Dealings

London, UK, 1 April 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, application has been made to AIM for the admission of 15,772 new ordinary shares of 5.0p each in the Company (the "New Ordinary Shares").

The New Ordinary Shares have been allotted pursuant to the purchase by Jim Winschel (Non-Executive Director) of new ordinary shares, under the terms of his letter of appointment as set out in the Company's announcement of 4 November 2014 which stated that Mr Winschel had entered into a binding commitment to purchase £4,000 of hVIVO plc new ordinary shares per quarter.

The New Ordinary Shares represent Mr Winschel's investment for the quarter ended March 2019. On 1 April 2019, Mr Winschel invested in an additional 15,772 ordinary shares, at a price of 25.36 pence per share.

Following admission of the New Ordinary Shares to trading on AIM, the total number of ordinary shares with voting rights in issue will be 82,957,337 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Admission of the New Ordinary Shares ("Admission"), which will rank pari passu in all respects with the Company's existing shares in issue, is expected to occur on 5 April 2019. Following Admission, Mr Winschel will be interested in a total of 109,445 ordinary shares of 5.0p in the Company, representing 0.1% of the Company's issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

For further information please contact:

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.